Under construction – not a live service
Sign in

2026-526942-29-00Not yet recruitingPhase 2/3

Prospective diagnostic performance of PET/CT using the novel fibroblast imaging tracer [18F]-AlF-FAPI-74 versus power doppler ultrasound in psoriasis patients with arthralgia: early detection of psoriatic arthritis

Source: EU CTIS (euclinicaltrials.eu) · Last updated 16 Oct 2026

Next steps

Brief summary (registry, in English)

Demonstrate that the diagnostic/predictive performance of [18F] AlF-FAPI-74 PET/CT is equivalent or superior to the current gold standard, power doppler ultrasound, for the development of clinical psoriatic arthritis within 2 years (non-inferiority study with non-inferiority limit 10%) in psoriasis patients with arthralgias

Status (registry)
Not yet recruiting
Phase (registry)
Phase 2/3
Study type
Interventional
Enrollment
270 (estimated)
First submitted
7 Aug 2026
Start date
1 Oct 2026
Lead sponsor
UZ Leuven
Diseases
Psoriasis
EU CT number
2026-526942-29-00

What you commit to

  • Study type: Interventional · Phase 2/3
  • Planned participants: 270
  • 2 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.

AI-kivonat: who the study is looking for

Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with psoriasis and joint pain that has lasted more than 2 weeks but less than 2 years. It compares a PET/CT scan with ultrasound for spotting early psoriatic arthritis.

Age
Older than 18 years
Sex
Men and women can join. Women must be post-menopausal, surgically sterile, or using effective contraception with a negative pregnancy test.
Disease stage
Psoriasis (plaque, guttate or pustular) confirmed by a dermatologist. Ongoing inflammatory joint or tendon-attachment pain for more than 2 weeks but less than 2 years, not caused by injury, with morning stiffness of more than 10 minutes.
Earlier treatment
People cannot have started systemic immunosuppressive treatment, including bDMARDs or tDMARDs, before the study scan.

Main reasons for not taking part

  • Current or past other inflammatory arthritis
  • Pregnancy, breast-feeding or planning pregnancy
  • Past or present cancer
  • Peripheral joint replacement
  • Known allergy to [18F] AlF-FAPI-74 or its ingredients

Read by machine on 9 Nov 2026.

Who cannot take part

Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Participation in a clinical scientific trial in the last 12 months with a radiation exposure caused by the experimental procedures greater than 1 mSv.
  • Use of systemic immunosuppressive therapy, including treatment with bDMARDs or tDMARDS, for psoriasis or another condition already started before study scan.

Other illness

  • Current or history of other inflammatory arthritis
  • Participant has a known hypersensitivity to [18F] AlF-FAPI-74 or the used excipients.
  • Diagnosis of other generalized dermatological conditions, such as atopic dermatitis, SLE, …….
  • History or presence of malignancy
  • Any disorder or condition, which in the Investigator’s opinion might jeopardise the participant’s safety or compliance with the protocol

Other

  • Participation in an interventional Trial with an investigational medicinal product (IMP) or device when the trial designs are not considered compatible by the study team.
  • Contraindication to PET scan (pregnancy, claustrophobia ……)
  • Patients with peripheral joint replacement
  • Participant is mentally or legally incapacitated, do not understand the trial design or is not willing or capable to undergo all trial-specific procedures.
  • Female who is pregnant (urinary hCG test will be performed in every WOCBP), breast-feeding or intends to become pregnant or is of child-bearing potential and not using an adequate, highly effective contraceptive (with a relatively high Pearl Index: natural methods, minipill outside postpartum period, spermicides or condoms in monotherapy or no usage of contraception when sexually active are not accepted).

Who the study is looking for

  • Voluntary written informed consent must be obtained prior to any screening procedures.
  • Subject is aged > 18 years
  • Female subjects should be (a) post-menopausal, or (b) surgically sterile, or (c) using effective contraceptive with negative pregnancy test.
  • Patients need to have a dermatologist confirmed clinical diagnosis of psoriasis, either plaque psoriasis, guttate psoriasis or pustular
  • Patient has persisting (inflammatory) arthralgia of the peripheral joints or entheses for more than 2 weeks, but less than 2 years not caused by trauma and with a morning stiffness of more than 10 minutes.

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on EU CTIS (euclinicaltrials.eu)

Sites (2)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
Universitair Ziekenhuis AntwerpenEdegemBelgiumNot yet recruiting
UZ LeuvenLeuvenBelgiumNot yet recruiting

Are you the coordinator? Confirm the details

This page is information, not medical advice. Discuss any trial with your doctor.